Showing results (61-70 of 95) with videos related to
Sort By:
Pageof 10
Clinical Genitourinary Cancer|December 28, 2013
Standard vs adapted sunitinib regimen in elderly patients with metastatic renal cell cancer: results from a large retrospective analysisUgo De Giorgi, Emanuela Scarpi, Cosimo Sacco, et al.Journal of Cellular Physiology|October 10, 2015
Body Mass Index and Treatment Outcomes in Metastatic Breast Cancer Patients Treated With EribulinMaddalena Barba, Laura Pizzuti, Isabella Sperduti, et al.Journal of Personalized Medicine|December 23, 2020
Palbociclib Plus Fulvestrant or Everolimus Plus Exemestane for Pretreated Advanced Breast Cancer with Lobular Histotype in ER+/HER2- Patients: A Propensity Score-Matched Analysis of a Multicenter Retrospective Patient SeriesArmando Orlandi, Elena Iattoni, Laura Pizzuti, et al.Breast Cancer Research and Treatment|September 20, 2014
Outcomes of HER2-positive early breast cancer patients in the pre-trastuzumab and trastuzumab eras: a real-world multicenter observational analysis. The RETROHER studyPatrizia Vici, Laura Pizzuti, Clara Natoli, et al.Frontiers in Oncology|July 13, 2023
Pathologic response and survival after neoadjuvant chemotherapy with or without pertuzumab in patients with HER2-positive breast cancer: the Neopearl nationwide collaborative studyAgnese Fabbri, Fabrizio Nelli, Andrea Botticelli, et al.Scientific Reports|September 8, 2017
Fasting glucose and body mass index as predictors of activity in breast cancer patients treated with everolimus-exemestane: The EverExt studyLaura Pizzuti, Paolo Marchetti, Clara Natoli, et al.Breast Cancer Research and Treatment|March 30, 2017
Dose intensity and efficacy of the combination of everolimus and exemestane (EVE/EXE) in a real-world population of hormone receptor-positive (ER+/PgR+), HER2-negative advanced breast cancer (ABC) patients: a multicenter Italian experienceMariangela Ciccarese, Alessandra Fabi, Luca Moscetti, et al.Oncotarget|October 4, 2017
Efficacy and safety of T-DM1 in the 'common-practice' of HER2+ advanced breast cancer setting: a multicenter studyAlessandra Fabi, Michelino De Laurentiis, Michele Caruso, et al.BMC Cancer|June 15, 2024
Safety and efficacy analysis of neoadjuvant pertuzumab, trastuzumab and standard chemotherapy for HER2-positive early breast cancer: real-world data from NeoPowER studyFabio Canino, Monica Barbolini, Ugo De Giorgi, et al.Breast (Edinburgh, Scotland)|August 10, 2018
T-DM1 and brain metastases: Clinical outcome in HER2-positive metastatic breast cancerAlessandra Fabi, Daniele Alesini, Enrichetta Valle, et al.Pageof 10